Answers are grounded in this paper and cite their sources.
Abstract 1. Etiocholanolone was employed in the assessment of bone marrow granulocyte reserves in a group of patients with acute leukemia prior to the administration of therapy. 2. Normal levels of circulating white blood cells and granulocytes and/or remission bone marrow status were often associated with abnormal test responses. 3. Individuals having a positive test response experienced significantly less hematologic toxicity following therapy than did those patients having a negative response. 4. Etiocholanolone proved to be a safe agent without significant side effects. 5. This test can be helpful in the prediction of toxicity following antileukemic therapy.
No takes yet. Share an insight, caveat, or question.
Godwin et al. (1968) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: